Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Director/PDMR Shareholding

18 Aug 2022 13:25

RNS Number : 5102W
Belluscura PLC
18 August 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura PLC

("Belluscura" or the "Company" or "Group")

 

Director / PDMR Shareholding

 

LONDON, U.K. AND PLANO, TX, U.S. (18 August 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, confirms that further to the notification on 10 August 2022 in respect of his exercise of options over 690,395 shares, Robert Rauker (CEO) has today transferred 455,064 shares to his ex-wife pursuant to a divorce settlement.

 

Following the transfer, Mr Rauker's holding is 1,191,015 shares and his total interest in the Company is 0.97% of the Company's issued share capital.

 

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP Communications

Anthony Dyer, Chief Financial Officer

 

SPARK Advisory Partners Ltd (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

Dowgate Capital Ltd (Broker & Bookrunner)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

 

MHP Communications (Media & Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Pete Lambie / Matthew Taylor 

or belluscura@mhpc.com

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Robert Rauker

2

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of £0.01 each in Belluscura plc

ISIN : GB00BD3B8Z11

b)

Nature of the transaction

(i) Transfer of shares

c)

Price(s) and volumes(s)

 

Price(s)

Volumes(s)

n/a

455,064

d)

Aggregated information

n/a

e)

Date of the transaction

17 August 2022

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPMTTMTBBBFT
Date   Source Headline
27th Jan 202312:41 pmRNSPlacing of Unsecured Convertible Loan Notes
24th Jan 20234:40 pmRNSSecond Price Monitoring Extn
24th Jan 20234:35 pmRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSBelluscura appoints Senior VP of Global Sales
13th Jan 20237:00 amRNSYear-end Trading Update
11th Jan 20234:40 pmRNSSecond Price Monitoring Extn
11th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Dec 20227:00 amRNSFirst international distribution agreement
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20222:06 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
14th Nov 202211:05 amRNSSecond Price Monitoring Extn
14th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSBelluscura receives certification to ISO standard
31st Oct 20225:46 pmRNSHolding(s) in Company
31st Oct 20225:41 pmRNSDirector/PDMR Shareholding
31st Oct 20225:38 pmRNSDirector/PDMR Shareholding
24th Oct 20227:00 amRNSBelluscura wins two HME Business Awards
23rd Sep 202211:45 amRNSHolding(s) in Company
20th Sep 20227:01 amRNSHalf-year Report
20th Sep 20227:00 amRNSBelluscura signs agreement with US distributor
6th Sep 20227:00 amRNSNotice of Results
18th Aug 20221:25 pmRNSDirector/PDMR Shareholding
10th Aug 20227:00 amRNSDirector/PDMR Shareholding
2nd Aug 20222:26 pmRNSAgreement with VGM, largest MSO in US-replacement
2nd Aug 202212:53 pmRNSAgreement with VGM, largest DSO in US-replacement
2nd Aug 20227:00 amRNSSupply Agreement with VGA, largest MSO in the US
15th Jul 20227:00 amRNSWarrant Exercise
14th Jul 20227:00 amRNSExercise of Warrants
30th Jun 20227:00 amRNSDirect to Consumer Sales and Distribution Plan
27th Jun 20227:00 amRNSLaunch of Next Gen X-PLOR Oxygen Concentrator
25th May 20221:19 pmRNSTR-1: Notification of major holdings
24th May 20225:27 pmRNSTR-1: Notification of major holdings
19th May 20227:00 amRNSBelluscura Expands its Patent Portfolio
17th May 202212:00 pmRNSApplications Announcement
13th May 202211:00 amRNSResult of Placing
12th May 20225:01 pmRNSProposed placing to raise £5.0m
25th Apr 20221:00 pmRNSResult of AGM
21st Apr 20227:00 amRNSSenior Management Appointment
7th Apr 20227:00 amRNSDAPA Contract
5th Apr 20226:31 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSenior Management Appointment
1st Apr 20227:00 amRNSNotice of AGM and Annual Report 2021
30th Mar 20227:00 amRNSManufacturing Agreement
22nd Feb 20227:00 amRNSFinal Results
27th Jan 202211:06 amRNSSecond Price Monitoring Extn
27th Jan 202211:00 amRNSPrice Monitoring Extension
24th Jan 20227:00 amRNSTrading Update and Notice of Preliminary Results
20th Jan 20222:32 pmRNSExercise of Warrants and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.